PCM
TTPH

Palisade Capital Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Palisade Capital Management’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-5,500
Closed -$5.22M – 584
2015
Q2 		$5.22M Buy
+5,500
New +$4.5M 0.13% 263

Other funds holding TTPH

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Palisade Capital Management's TTPH Position: Q3 2015 in Review

Palisade Capital Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2015, closing a stake of 5,500 shares — an estimated $5.22M sold.

Palisade Capital Management first reported a position in TTPH in Q2 2015 and held it in 1 quarter. The position peaked at $5.22M in Q2 2015. 105 funds tracked by Wall St. Rank hold TTPH as of Q3 2015.

  • Palisade Capital Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • Palisade Capital Management sold 5,500 Tetraphase Pharmaceuticals, Inc. shares in Q3 2015, an estimated $5.22M.
  • Palisade Capital Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2015 and held it in 1 quarter.
  • Palisade Capital Management's Tetraphase Pharmaceuticals, Inc. position peaked at $5.22M in Q2 2015.
  • 105 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2015.

Based on Palisade Capital Management's 13F filing for Q3 2015, filed 29 Oct 2015.